DARE - Because Entrepreneurs Do

According to a new technical market research report, ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS (PHM062A) from BCC Research (www.bccresearch.com), the value of the Alzheimer's disease market is an estimated $8 billion in 2009, but is expected to increase to $9.6 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 3.7%.

The largest segment of the market, disease-modifying therapeutics, is projected to decrease at a CAGR of -2.6%, dropping to $5.2 billion in 2014, after being valued at nearly $6 billion in 2009.

Diagnostics/biomarkers, the second-largest segment of the market, is estimated at $1.2 billion in 2009, and is expected to increase at a 5-year CAGR of 19.6% to reach nearly $2.9 billion in 2014.

The therapeutics for treatment of symptoms segment is expected to have a 5-year CAGR of 5.1%, with values of $567 million in 2009 and $726 million in 2014.

The smallest segment of the market, imaging products, is projected to have a healthy 5-year CAGR of 18.7%, rising from $361 million in 2009 to $852 million in 2014.

Alzheimer's disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients increases and the frustration with a lack of effective treatments grows. Though many marketed drugs have been approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments.

BCC's key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market, and outline key factors that will influence the therapeutic area in the next few years.

Source: Indiaprwire

Comments (0)

Subscribe to this comment's feed